CompletedPhase 1

Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate

France26 participantsStarted 2009-02-09

Plain-language summary

The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Rare tumor * metastatic disease or locally advanced disease, inoperable, with no standard treatment * At least 28 days since the prior treatment * Measurable disease with at least one measurable lesion Exclusion Criteria: * Medullary insufficiency * Cystitis, haemorrhagic cystitis * Hepatic porphyria

What they're measuring

For safety: NCI-CTCAE scale version 3.0

Timeframe: 42 days

Trial details

NCT IDNCT01046487

SponsorCentre Oscar Lambret

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-04

View on ClinicalTrials.gov More Cancer trials